Cell therapy weekly: IND for allogeneic cell therapy indicated for scleroderma

This week: Talaris Therapeutics (MS, USA) receives IND for their allogeneic scleroderma therapy, Rigenerand SRL (Modena, Italy) receives funding to improve 3D bioreactor technology for EV production and Vor Biopharma (MA, USA) closes US$110 million funding for engineered stem cell therapy. The news highlights: IND for allogeneic cell therapy indicated for scleroderma Grant for development of 3D bioreactors for cGMP EV production US$110 million financing for engineered stem cell therapy for hematologic malignancies VIVEBiotech and Xyphos Biosciences to collaborate on convertibleCAR-T™ therapy IND for allogeneic cell therapy indicated for scleroderma FDA has approved the Investigational New Drug application (IND) for...